Stock is now quite oversold. Since it is now being traded primarily on a technical basis, expect a move back to $1.75 shortly. Any news on a drug program will send it above $1.75. If you want more get it now.
John, glad you are still here.
I'd take either but it seems like the dengue vaccine is due for news. If it was either of the two you mentioned I think the stock would be much higher. My sense is that a deal will get "leaked".
Do you think BMY is seriously looking at Vaxfectin?
No quote from Vijay. Looks like he is being phased out. We can only hope.
winallin12 You posted 1039 times since March 30th 2012. Who are you? Who do you work for? How much are you getting paid for this?
The donor pays the tax. VJ avoided what could be a large tax. The value of the gift should be much greater before the end of the month. It makes a lot of sense.
He needs to make the gift before the stock pops other wise he has to pay a tax on an amount over 14k
It tells you they intend to hire quite a few new employees from established biotechs and will need to put large option packages in place to recruit them away from their current employers. Typically you have to at least match the amount of options an employee is giving up when they leave their current employer.
I just pinged Dr. Verjee...
"I have just completed some additional analyses that suggest medians [in the comparator arm] as high as 16 months give Allovectin an excellent chance of success provided the number of [death] events is 290 or less. I think the true number is 275 events."
If they don't release top line results on the 12th VICL is set up for a wicked Bear Raid which will drop the stock a buck at least as all the bears and shorts will flood this MB with comments on bad results.
It's happened before on other small biotechs.
To me, the most significant comment was his steadfast commitment to "12-14 months" for the control arm. He has NEVER stated an estimate above 14 months.